Marktanalyse - Partnerships, Licensing, Investments and M&A Deals and Trends for May 2012 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for May 2012 in Pharmaceuticals


Summary


GlobalData's 'Partnerships, Licensing, Investments and M&A Deals and Trends for May 2012 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in May 2012. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.


Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the last six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include — North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.


Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

1 Table of contents

1 Table of contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 Pharmaceuticals & Healthcare, Global, Deal Summary, 7

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, May 2012 7

2.2 Pharmaceuticals & Healthcare, Global, Major Deals, May 2012 9

2.2.1 DaVita To Acquire HealthCare Partners, Doctor Network Operator, For Up To $4.7 Billion 9

2.2.2 Agilent Technologies To Acquire Dako From EQT For $2.2 Billion 9

2.2.3 Novartis To Acquire Fougera Pharma, Dermatology Company, For $1.5 Billion 10

2.2.4 Royalty Pharma Acquires BG-12 And Fumaderm From Fumapharm For $761 Million 10

2.2.5 Piramal Healthcare Completes Acquisition Of Decision Resources From Providence Equity For $625 Million 10

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals and Deal Values, May 2012 11

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 12

3.1 Pharmaceuticals & Healthcare, Global, M&A, May 2012 12

3.1.1 Top M&A Deals in May 2012 13

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, December 2011-May 2012 14

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, May 2012 15

3.2.1 Top Equity Offering Deals in May 2012 16

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, December 2011 - May 2012 17

3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, May 2012 18

3.3.1 Top PE/VC Deals in May 2012 19

3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, May 2012 20

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, May 2012 21

3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, December 2011 - May 2012 22

3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, December 2011 - May 2012 23

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, May 2012 24

4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, May 2012 24

4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, December 2011 - May 2012 25

4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), May 2012 26

4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, May 2012 27

4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), December 2011 - May 2012 28

4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals and Deal Values (US$ m), December 2011 - May 2012 29

4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), December 2011 - May 2012 30

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, May 2012 31

5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, May 2012 31

5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2012 32

5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, May 2012 33

5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, May 2012 33

5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, December 2011 34

5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), December 2011 - May 2012 35

5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), December 2011 - May 2012 36

5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), December 2011 - May 2012 37

5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), December 2011 - May 2012 38

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 39

6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, May 2012 39

6.1.1 Oncology - Deals of the Month 40

6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, May 2012 41

6.2.1 Central Nervous System - Deals of the Month 42

6.3 Pharmaceuticals & Healthcare, Global, Immunology Deals, May 2012 43

6.3.1 Immunology - Deal of the Month 44

6.4 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, May 2012 45

6.4.1 Infectious Diseases - Deals of the Month 46

6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorder Deals, May 2012 47

6.5.1 Metabolic Disorders - Deal of the Month 48

6.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, May 2012 49

6.6.1 Cardiovascular - Deal of the Month 50

6.7 Pharmaceuticals & Healthcare, Global, Dermatology, Deals, May 2012 51

6.7.1 Dermatology - Deals of the Month 52

7 Deal Summary by Geography 53

7.1 Pharmaceuticals & Healthcare, North America Deals, May 2012 53

7.1.1 North America - Deals of the Month 54

7.2 Pharmaceuticals & Healthcare, Europe, Deals, May 2012 55

7.2.1 Europe - Deals of the Month 56

7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, May 2012 57

7.3.1 Asia-Pacific - Deals of the Month 58

7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, May 2012 59

7.4.1 Rest of the World - Deals of the Month 60

8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 61

8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, December 2011 - May 2012 61

8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, December 2011 - May 2012 62

9 Further Information 63

9.1 Methodology 63

9.2 About GlobalData 63

9.3 Contact Us 64

9.4 Disclosure information 64

9.5 Disclaimer 64





1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 8

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, May 2012 9

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), May 2012 11

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 12

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, May 2012 13

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, December 2011 - May 2012 14

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 15

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, May 2012 16

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 17

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 18

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, May 2012 19

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, December 2011 - May 2012 20

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), May 2012 21

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 22

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, December 2011 - May 2012 23

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 24

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 25

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), December 2011 - May 2012 26

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), May 2012 27

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), December 2011 - May 2012 28

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, December 2011 - May 2012 29

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), December 2011 - May 2012 30

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 31

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), December 2011 - May 2012 32

Table 25: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Deal Value, May 2012 33

Table 26: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, May 2012 33

Table 27: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, December 2011 34

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal values (US$ m), December 2011 - May 2012 35

Table 29: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), May 2012 36

Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, December 2011 - May 2012 37

Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), May 2012 38

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 39

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 41

Table 34: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 43

Table 35: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 45

Table 36: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 47

Table 37: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 49

Table 38: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 51

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 54

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 55

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 57

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 59

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 61

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 62





1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 7

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%) and Deal Values (%),May 2012 11

Figure 3: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 12

Figure 4: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, December 2011 - May 2012 14

Figure 5: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 15

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 17

Figure 7: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 18

Figure 8: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, December 2011 - May 2012 20

Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%) and Deal Values (%), May 2012 21

Figure 10: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 22

Figure 11: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 24

Figure 12: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 25

Figure 13: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), December 2011 - May 2012 26

Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), December 2011 - May 2012 28

Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, December 2011 - May 2012 29

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), December 2011 - May 2012 30

Figure 17: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 31

Figure 18: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), December 2011 - May 2012 32

Figure 19: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 35

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), December 2011 - May 2012 36

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals and Deal Values (US$ m), December 2011 - May 2012 37

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), May 2012 38

Figure 23: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 39

Figure 24: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 41

Figure 25: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 43

Figure 26: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 45

Figure 27: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 47

Figure 28: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 49

Figure 29: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 51

Figure 30: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 53

Figure 31: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 55

Figure 32: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 57

Figure 33: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 59

Figure 34: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 61

Figure 35: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), December 2011 - May 2012 62

• ICT Spend Predictions in Large Brazilian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Large Canadian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Large French Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Large German Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Large Mexican Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Large UK Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Large US Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized Brazilian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized Canadian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized French Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized German Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized Mexican Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized UK Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized US Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Small Brazilian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Small Canadian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Small French Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Small German Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Small Mexican Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Small UK Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013